Skip to main content

Xerosis

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
SQINPhase 2/31 trial
Active Trials
NCT02429206Completed10Est. Jun 2015
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
Cosmetic productN/A1 trial
Active Trials
NCT04181177Completed29Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Nordic PharmaSQIN
Pierre FabreCosmetic product

Clinical Trials (2)

Total enrollment: 39 patients across 2 trials

Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis

Start: Apr 2015Est. completion: Jun 201510 patients
Phase 2/3Completed
NCT04181177Pierre FabreCosmetic product

Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments

Start: Feb 2019Est. completion: Mar 202229 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.